Insight Molecular Diagnostics Inc. (IMDX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $60.87M
Last updated: Nov 17, 2026 at 4:10 PM ET
Insight Molecular Diagnostics Inc. (IMDX) Stock Chart
Insight Molecular Diagnostics (IMDX) has a latest price of $1.78 on Nov 17, 2026. Its price fell 75.9% over the past 12 months. The month-end price fell 96.3% over the 10 years through Oct 2026, a compound annual decline of 28.2%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $151.00 in Sep 2017 and its lowest $2.07 in Jan 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart IMDX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for IMDX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 59.4%, and over 6 months it fell 68.0%. The month-end price rose 29.6% over the 3 years through Oct 2026, a compound annual rate of 9.0%.
| Period | Change |
|---|---|
| 1 month | -38.4% |
| 3 months | -59.4% |
| 6 months | -68.0% |
| 12 months | -75.9% |
| 12 months, with dividends | -75.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +29.6% | +9.0% |
| 5 years | -95.5% | -46.2% |
| 10 years | -96.3% | -28.2% |
Price by Year
Its best calendar year was 2025, when the price rose 215.1%, and its weakest was 2022, when it fell 85.2%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $2.96 | -60.5% |
| 2025 | $7.50 | +215.1% |
| 2024 | $2.38 | -4.8% |
| 2023 | $2.50 | -61.0% |
| 2022 | $6.42 | -85.2% |
| 2021 | $43.40 | -9.2% |
| 2020 | $47.80 | +6.2% |
| 2019 | $45.00 | +63.0% |
| 2018 | $27.60 | -70.3% |
| 2017 | $93.00 | -34.0% |
Trading Range
The price is 44.3% below its 50-day average of $3.20 and 60.3% below its 200-day average of $4.48.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.78 | |
| 50-day average | $3.20 | -44.3% |
| 200-day average | $4.48 | -60.3% |
Price Risk
Over 3 years, its largest fall from a peak was 79.0%.
| Measure | Value |
|---|---|
| 1-year beta | 2.64 |
| Largest fall, 1 year | -76.3% |
| Largest fall, 3 years | -79.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About IMDX
What is IMDX's 1-year price change?
Insight Molecular Diagnostics's price fell 75.9% over the past 12 months. With dividends included, the 12-month total return was -75.9%.
What is IMDX's 5-year price change?
Insight Molecular Diagnostics's month-end price fell 95.5% over the 5 years through Oct 2026, a compound annual decline of 46.2%. These figures leave out dividends.
What is IMDX's beta?
Insight Molecular Diagnostics's 1-year beta against the S&P 500 is 2.64, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 76.3%.
Is the IMDX chart free?
Yes. Advanced Charting for IMDX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
IMDX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors